To evaluate whether the use of dutasteride is associated with a lower risk of transrectal prostate biopsy-associated urinary tract infection (TPBA-UTI) among men in the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study.
Retrospective analysis of 6045 men undergoing 2-year repeat prostate biopsy in REDUCE. Participants were randomized to receive dutasteride 0.5 mg or placebo daily. TPBA-UTI was defined as the presence of urinary symptoms and the prescription of antibiotics by the treating physician within 30 days after biopsy. Severe TPBA-UTI was defined as TPBA-UTI requiring hospitalization. Comparison of TPBA-UTI between treatment arms was done using Chi-square test and logistic regression adjusting for participant characteristics.
Of the subjects included in the study, 3067 (50.7%) were randomized to the placebo arm and 2978 (49.3%) to the dutasteride arm. A total 51 (0.8%) men had TPBA-UTI, including 38 (1.2%) in the placebo arm and 13 (0.4%) in the dutasteride arm (univariable relative risk [RR] = 0.35, P = 0.001; multivariable odds ratio [OR] = 0.34, P = 0.003). The number needed to treat (NNT) to prevent one TPBA-UTI was 125 subjects. Of these, 14 (28%) had severe TPBA-UTI, including 12 (0.4%) in the placebo arm and only 2 (0.07%) in the dutasteride arm (univariable RR = 0.17, P = 0.021; multivariable OR = 0.17, P = 0.031). The NNT to prevent one severe TPBA-UTI was 309 subjects.
Among men undergoing a 2-year repeat prostate biopsy, the use of dutasteride for 2 years was associated with a reduced the risk of overall and severe TBPA-UTI. CLINICALTRIALS.
NCT00056407.
World journal of urology. 2017 Apr 10 [Epub ahead of print]
Daniel M Moreira, Gerald L Andriole, J Curtis Nickel, Claus G Roehrborn, Ramiro Castro-Santamaria, Stephen J Freedland
Department of Urology, University of Illinois at Chicago, 820 S Wood Street, CSN Suite 515, Chicago, IL, 60612, USA. ., Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA., Department of Urology, Queen's University, Kingston, ON, Canada., Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA., GlaxoSmithKline Inc., Global R&D, King of Prussia, PA, USA., Division of Urology, Department of Surgery, Cedars Sinai Medical Center, Los Angeles, CA, USA.